Biotech and Pharmaceuticals
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1 pills for obesity are closer than ever. 2026 is likely the year that two new oral weight loss […]
Read More
What Trump’s reclassification of pot and CBD could mean for seniors, research and stocks
Tarek Adieh, of Tampa, Florida, looks at cannabis flower from wholesaler Dep Kings at CHAMPS Trade Show at the Palmer Events Center Thursday, Sept. 11, 2025. Jay Jannar | Hearst Newspapers | Getty Images President Donald Trump is expected to sign an executive order this week that would broadly expand access to cannabis. Industry advocates, […]
Read More
Pfizer’s modest 2026 outlook shows its big investments will take time to pay off
Smith Collection | Archive Photos | Getty Images Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs. Those hurdles aren’t surprising or new for Pfizer, which has seen a dramatic decline in Covid vaccine and antiviral sales […]
Read More
Europe’s best-performing stock is up 1,400% this year. Here’s what’s next
Key Points Abivax shares are up more than 1,400% year to date as investors are optimistic about the prospects of its treatment for ulcerative colitis. “We are certainly excited about the work we are doing, and we’ve been greeted again by the medical community as becoming possibly this next standard of care in ulcerative colitis,” […]
Read More
Healthy Returns: FDA may add its strongest safety warning to Covid vaccines. Here’s what to know
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food and Drug Administration may add its strongest safety warning to Covid shots – marking another major shift in vaccine oversight. It could also expand a […]
Read More
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]
Read More
Eli Lilly’s next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Thursday said its next-generation obesity drug delivered strong weight loss and reduced knee arthritis pain in a late-stage study, clearing the first of several upcoming trials on the weekly injection. The […]
Read More
Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend […]
Read More
A biotech stock for investors scared to invest in the risky industry
Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand’s Monday closing price of $184.67. Shares have soared nearly 79% this year. LGND YTD mountain LGND YTD chart […]
Read More
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company’s pill
Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. John Thys | Reuters Pfizer on Tuesday said it has struck an […]
Read More